Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Clinical Trial ID NCT01015833

PubWeight™ 13.63^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01015833

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Trial watch: Chemotherapy with immunogenic cell death inducers.	Oncoimmunology	2012	1.33
2	Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma.	World J Hepatol	2013	1.23
3	Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics.	Clin Med Insights Oncol	2014	1.17
4	Hepatocellular carcinoma: natural history, current management, and emerging tools.	Biologics	2012	1.10
5	Antiangiogenic therapies for advanced hepatocellular carcinoma.	Oncologist	2013	0.94
6	A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma.	J Hepatol	2013	0.93
7	Targeting the tumor stroma in hepatocellular carcinoma.	World J Hepatol	2015	0.86
8	Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.	Gastroenterol Hepatol (N Y)	2013	0.82
9	Molecular targeting agents associated with transarterial chemoembolization or radiofrequency ablation in hepatocarcinoma treatment.	World J Gastroenterol	2014	0.80
10	Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights.	World J Gastroenterol	2014	0.78
11	Hepatocellular carcinoma: Consensus, controversies and future directions. A report from the Canadian Association for the Study of the Liver Hepatocellular Carcinoma Meeting.	Can J Gastroenterol Hepatol	2015	0.77
12	Drug development for hepatocellular carcinoma: knowing the past helps to understand the future.	Oncologist	2014	0.76
13	What's New in Transarterial Therapies for Hepatocellular Carcinoma?	Gastrointest Cancer Res	2012	0.75
14	Potentiality and boundaries of use of sorafenib in patients with hepatocellular carcinoma: awaiting the results of ongoing clinical trials.	Cancers (Basel)	2012	0.75
15	Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma.	Gastroenterol Hepatol (N Y)	2010	0.75